Our mission is to enable access to high quality, affordable,
specialty NGS testing, performed by any NGS laboratory as
clinical grade tests, closer to home, for all patients.
Gang Song, Ph.D.
Founder, President and Chief Executive Officer Dr. Gang Song is the founder of Pillar Biosciences, who co-invented Pillar Biosciences’ SLIMamp® technology. He subsequently co-founded Affyimmune Therapeutics, a cellular immunotherapy company, and is also a Venture Partner at ORI Capital. Previously, Dr. Song held positions of increasing responsibility at LabCorp (previously Genzyme Genetics) and IQuum (subsequently acquired by Roche Molecular Diagnostics). Dr. Song completed his postdoctoral training in Timothy Springer's lab at Harvard Medical School and received his Ph.D. from Shanghai Medical College of Fudan University, China.
Zhaohui Wang, Ph.D.
Co-founder and Chief Scientific Officer Dr. Zhaohui Wang co-founded Pillar Biosciences, and co-invented SLIMamp technology. Previously, she held positions of increasing responsibility at LabCorp (previously Genzyme Genetics) and IQuum (subsequently acquired by Roche Molecular Diagnostics). Dr. Wang received her Ph.D. in Cellular and Molecular Biology from the University of Massachusetts, Amherst.
Chief Financial Officer Rick Shea served as the Chief Financial Officer of Syndax Pharmaceuticals, Inc. from February 2017 to July 2020. Rick previously served as a member of the Syndax Pharmaceuticals board of directors from January 2014 to February 2017. From July 2007 through December 2016, he served as Senior Vice President and Chief Financial Officer of Momenta Pharmaceuticals Inc., a publicly traded biotechnology company, and was its Vice President and Chief Financial Officer since October 2003. Prior to joining Momenta, Rick served as Chief Operating Officer and Chief Financial Officer of Variagenics Inc., a publicly traded pharmacogenomics company, that was merged with Hyseq Pharmaceuticals Inc., and as Vice President, Finance of Genetics Institute, Inc., a publicly traded biotechnology company, which was acquired by Wyeth Pharmaceuticals, Inc., which was then acquired by Pfizer, Inc. Rick received an AB from Princeton University and an MBA from the Public Management Program at Boston University.
Chief Business Officer Laura possesses close to 30 years of leadership experience in the molecular diagnostics, biotechnology and pharmaceutical industries. Most recently, Ms. Beggrow served as President of Molecular Diagnostics at HTG Molecular. Prior to this, Laura was the Chief Commercial Officer at Celcuity where she led early corporate strategic planning and clinical pipeline development for three years. She began her molecular diagnostic career in 2004 at Genomic Health serving as VP of Sales & Marketing and leading the commercial organization for close to nine years. Prior to Genomic Health, she served in a variety of commercial leadership positions in specialty therapeutics (cardiovascular, neurology and oncology) with big pharma, biotech and smaller start-up organizations. Laura is an effective business leader and helped take two companies successfully public (Celcuity and Genomic Health). She holds a Bachelor of Science Degree in Nursing from The Ohio State University.
Martin Zillmann, Ph.D.
Chief Operating Officer Dr. Martin Zillmann, Pillar Biosciences' Chief Operating Officer, has a long history in nucleic acid diagnostics that started with his role as Director of Assay Development at Variagenics, a pioneer in the field of personalized medicine. Most recently, he served as Head of the Technology Office for the Process Solutions business of MilliporeSigma. Dr. Zillmann holds a Ph.D. in Biochemistry from Rice University.